For patients the value of medicines is all about how it works for their particular condition and that their benefit and safety balance fits with the individual goals for treatment, ideally discussed and agreed upon with their treating doctor. This was the main message of EFA’s Susanna Palkonen in her presentation at the European Parliament, during the launch of the new sector group ‘Value added medicines’ of the Medicines for Europe, who represents the European generic medicines industry. According to them, ‘value added medicines’ are based on generics, molecules that are off patent but new value is added.
In case of respiratory drugs, this could be for example adding a more effective inhaler to deliver the medicine into lungs or new dosages fitting better diverse patients. As adherence to treatment is one key issue in optimising our healthcare, we also had the opportunity to present the exiting results in our HEY YA HEalth Literacy, Young Patients with Asthma and Adherence to Treatment Report to the audience of MEPs, industry, healthcare professional and patient representatives from different disease areas who were present.
If you want to know more, please read Susanna's presentation on Patients' Value and Sustainability.